Rational modification of a candidate cancer drug for use against Chagas disease (Journal of Medicinal Chemistry (2009) 52, (1639) DOI: 10.1021/jm801313t);Rational modification of a candidate cancer drug for use against chagas disease

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1639-1647

  Kraus, James M ^a   Verlinde, Christophe L M J ^a   Karimi, Mandana ^a   Lepesheva, Galina I ^b   Gelb, Michael H ^a   Buckner, Frederick S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 AMINO 5 BROMOPHENYL)(3 CHLORO 2 METHYLPHENYL)METHANONE; (4 CHLOROPHENYL)(1 METHYL 1H IMIDAZOL 5 YL)METHANONE; 2 AMINO 5 BROMO N METHOXY N METHYLBENZAMIDE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4-CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4-CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 2 METHYLQUINOLINE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4-CHLOROPHENYL)(HYDROXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL)QUINOLIN 2(1H) ONE; 4 (3 CHLORO 2 METHYLPHENYL) 6 ((4-CHLOROPHENYL)(METHOXY)(1 METHYL 1H IMIDAZOL 5 YL)METHYL) 1 METHYLQUINOLIN 2(1H) ONE; 4 CHLORO N METHOXY N METHYLBENZAMIDE; 6 BROMO 4 (3 CHLORO 2 METHYLPHENYL) 2 METHOXYQUINOLINE; 6 BROMO 4 (3 CHLORO 2 METHYLPHENYL)QUINOLIN 2(1H) ONE; KETOCONAZOLE; POSACONAZOLE; PROTEIN FARNESYLTRANSFERASE; STEROL 14ALPHA DEMETHYLASE; TIPIFARNIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG STRUCTURE; DRUG TARGETING; FEMALE; MOUSE; NONHUMAN; TOXICITY; TRYPANOSOMA CRUZI;

EID: 64349102737     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900929t     Document Type: Erratum

References (31)

1. Hucke, O.; Gelb, M. H.; Verlinde, C. L.; Buckner, F. S. The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas Disease. J. Med. Chem. 2005, 48, 5415-5418.
2. Sparreboom, A.; Marsh, S.; Mathijssen, R. H.; Verweij, J.; McLeod, H. L. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Inyest.New.Drugs. 2004, 22, 285-9.
3. Zujewski, J.; Horak, I. D.; Bol, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 2000, 18, 927-941.
4. Venet, M.; End, D.; Angibaud, P. Farnesyl protein transferase inhibitor ZARNESTRA R115777-history of a discovery. Curr. Top. Med. Chem. 2003,3.
5. Molina, J.; Martins-Filho, O.; Brener, Z.; Romanha, A. J.; Loebenberg, D.; Urbina, J. A. Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob. Agents Chemother. 2000, 44, 150-5.
6. Bennett, F.; Saksena, A. K.; Lovey, R. G.; Liu, Y.; Patel, N. M.; Pinto, P.; Pike, R.; Jao, E.; Girijavallabhan, V. M.; Ganguly, A. K.; Loebenberg, D.; Wang, H.; Cacciapuoti, A.; Moss, E.; Menzel, F.; Hare, R. S.; Nomeir, A. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg. Med. Chem. Lett. 2006, 16, 186-190.
7. Saksena, A. K.; Girijavallabhan, V. M.; Wang, H.; Lovey, R. G.; F., G.; Mergelsberg, I.; Puar, M. S. Stereoselective Grignard additions to N-formyl hydrazone: a concise synthesis of NoxafilR side chain and a synthesis of NoxafilR. Tetrahedron Lett. 2004, 45, 8249-8251.
8. Saksena, A. K.; Girijavallabhan, V. M.; Lovey, R. G.; Pike, R. E.; Wang, H.; Liu, Y.; Ganguly, A. K.; Bennett, F. Tetrahydrofuran Antifungals. WO 1996/038443 A1, 1996.
9. Reid, T. S.; Beese, L. S. Crystal Structures of the Anticancer Clinical Candidates R115777 (Tipifarnib) and BMS-214662 Complexed with Protein Farnesyltransferase Suggest a Mechanism of FTI Selectivity. Biochemistry 2004, 43, 6877-6884.
10. Podust, L. M.; Poulos, T. L.; Waterman, M. R. Crystal structure of cytochrome P450 14a-sterol demethylase (CYP51) from Mycobac- terium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3068-3073.
11. Angibaud, P. R.; Venet, M. G.; Filliers, W.; Broeckx, R.; Ligny, Y. A.; Muller, P.; Poncelet, V. S.; End, D. W. Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA. Eur. J. Org. Chem. 2004, 479-486.
12. Frye, S. V.; Johnson, M. C.; Valvano, N. L. Synthesis of 2-aminoben- zophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide. J. Org. Chem. 1991, 56, 3750-3752.
13. Venet, M. G.; Angibaud, P. R.; Muller, P.; Sanz, G. C. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives. WO 1997/021701 A1, 1997.
14. Venet, M. G.; Angibaud, P. R.; Muller, P.; Sanz, G. C. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives. U.S. Patent US 6037350, 2000.
15. Yang, B. V. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agent. WO 2000/047574 A1, 2000.
16. Vejdelek, Z.; Holubek, J.; Ryska, M.; Koruna, I.; Svatek, E.; Budesinsky, M.; Protiva, M. Reactions of 4-Chloro-1-nitrobenzene with o-Substituted Phenylacetonitriles; Synthesis of 8-Chloro-1- methyl(and methylthiomethyl)-6-(2- substituted phenyl)-4H-s-triazolo[4,3- a]-1,4-benzodiazepines. Collect. Czech. Chem. Commun. 1987, 52, 2545-2563.
17. Faller, J. W.; Lavoie, A. R. Enantioselective Syntheses of Nonracemic Benzyl-a-D-Alcohols via Catalytic Transfer-Hydrogenation with Ru, Os, Rh, and Ir Catalysts. Organometallics 2002, 21, 3493-3495.
18. Mitchell, R. H.; Lai, Y. Syntheses and Reactions of the First Dithia[3.1.3.1]metacyclophanes, [2.1.2.1]Metacyclophanes, and [2.1.2.1]-Metacyclophanes. J. Org. Chem. 1984, 49, 2534-2540.
19. Friedman, L.; Shechter, H. Preparation of Nitriles from Halides and Sodium Cyanide. An Advantageous Nucleophilic Displacement in Dimethyl Sulfoxide. J. Org. Chem. 1960, 25, 877-879.
20. Walsh, D. A. The Synthesis of 2-Aminobenzophenones. Synthesis 1980, (Sept.), 677-688.
21. Pratt, E. F.; Draper, J. D. Reaction Rates by Distillation. I. The Etherification of Phenylcarbinols and the Transetherification of their Ethers. J. Am. Chem. Soc. 1949, 71, 2846-2849.
22. Araujo, M. S.; Martins-Filho, O. A.; Pereira, M. E.; Brener, Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother. 2000, 45, 819-824.
23. Brener, Z.; Cancado, J. R.; Galvao, L. M.; da Luz, Z. M.; Filardi, L. S.; Pereira, M. E.; Santos, L. M.; Cancado, J. R. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz 1993, 88, 149-153.
24. Bustamante, J. A.; Bixby, L. M.; Tarleton, R. L. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat. Med. 2008, 14, 542-550.
25. Corrales, M.; Cardozo, R.; Segura, M. A.; Urbina, J. A.; Basombrio, M. A. Comparative Efficacies of TAK-187, a Long-Lasting Ergosterol Biosynthesis Inhibitor, and Benznidazole in Preventing Cardiac Damage in a Murine Model of Chagas' Disease. Antimicrob. Agents Chemother. 2005, 49, 1556-1560.
26. Urbina, J. A.; Payares, G.; Sanoja, C.; Lira, R.; Romanha, A. J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 2003, 21, 27-38.
27. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput-Aided Mol. Des. 1997, 11, 333-344.
28. Yokoyama, K.; Zimmerman, K.; Scholten, J.; Gelb, M. H. Differential Prenyl Pyrophosphate Binding to Mammalian Protein Geranylgera- nyltransferase-I and Protein Farnesyltransferase and Its Consequence on the Specificity of Protein Prenylation. J. Biol. Chem. 1997, 272, 3944-3952.
29. Van Voorhis, W. C.; Rivas, K. L.; Bendale, P.; Nallan, N.; Horney, C.; Barrett, L. K.; Bauer, K. D.; Smart, B. P.; Ankala, S.; Hucke, O.; Verlinde, C. L. M. J.; Chakrabarti, D.; Strickland, C.; Yokoyama, K.; Buckner, F. S.; Hamilton, A. D.; Williams, D. K.; Lombardo, L. J.; Floyd, D.; Gelb, M. H. Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase. Antimicrob. Agents Chemother. 2007, 51, 3659-3671.
30. Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Voorhis, W. C. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing β-galactosidase. Antimicrob. Agents Chemother. 1996, 40, 2592-7.
31. Van Voorhis, W. C.; Eisen, H. Fl-160. A surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue. J. Exp. Med. 1989, 169, 641-652.